Tenpoint Therapeutics and PHIL Partner for YUVEZZI Direct-to-Patient Program

New cash program aims to make novel presbyopia therapy more accessible and affordable.

Apr. 2, 2026 at 5:32pm

Got story updates? Submit your updates here. ›

A translucent X-ray photograph of a human eye, with the internal structures glowing softly against a dark background, conceptually representing the importance of vision health and the development of new therapies to address vision problems.A novel eye drop therapy aims to provide a more accessible treatment option for the millions affected by age-related vision loss.Scottsdale Today

Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., a digital health platform, have announced the launch of a Direct-to-Patient cash program for YUVEZZI, the first and only dual-agent prescription eye drop for presbyopia. The program is designed to make this novel therapy more accessible and affordable for patients.

Why it matters

Presbyopia, the age-related loss of near vision, affects nearly 2 billion people worldwide. The launch of YUVEZZI represents a significant advancement in presbyopia treatment, but cost and accessibility have been barriers for many patients. This new Direct-to-Patient program aims to address those challenges and improve patient access to this innovative therapy.

The details

The YUVEZZI Direct-to-Patient cash program will allow patients to purchase the medication directly from PHIL's online platform without the need for insurance. PHIL will handle all aspects of the ordering, fulfillment, and delivery process, providing a convenient and streamlined experience for patients.

  • YUVEZZI was approved by the FDA in March 2026.
  • The Direct-to-Patient program launched on April 2, 2026.

The players

Tenpoint Therapeutics

A leading ophthalmic manufacturer and developer of YUVEZZI, the first and only dual-agent prescription eye drop for presbyopia.

PHIL Inc.

An all-in-one digital hub and Direct-to-Patient platform that will handle the ordering, fulfillment, and delivery of YUVEZZI through the new cash program.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with PHIL to launch this innovative Direct-to-Patient program and make YUVEZZI more accessible to the millions of people living with presbyopia.”

— Dr. Sarah Lim, Chief Medical Officer, Tenpoint Therapeutics

“Our mission is to empower patients with more affordable and convenient access to innovative therapies, and the YUVEZZI program is a perfect example of how we can achieve that goal.”

— Alex Slavsky, CEO, PHIL Inc.

What’s next

Tenpoint Therapeutics and PHIL plan to expand the YUVEZZI Direct-to-Patient program to additional markets in the coming months.

The takeaway

The launch of the YUVEZZI Direct-to-Patient cash program represents a significant step forward in improving access and affordability for a novel presbyopia treatment, addressing a major unmet need for the millions of people affected by this condition.